Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.